Yang Y, Hong M, Lian WW, Chen Z. Review of the pharmacological effects of astragaloside IV and its autophagic mechanism in association with inflammation. World J Clin Cases 2022; 10(28): 10004-10016 [PMID: 36246793 DOI: 10.12998/wjcc.v10.i28.10004]
Corresponding Author of This Article
Zhi Chen, Doctor, Academic Fellow, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Qingchun Road, Hangzhou 310003, Zhejiang Province, China. zjuchenzhi@zju.edu.cn
Research Domain of This Article
Pharmacology & Pharmacy
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Ying Yang, Meng Hong, Wen-Wen Lian, Zhi Chen, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, Zhejiang Province, China
Author contributions: Yang Y wrote this review; Chen Z conceived this review; Hong M and Lian WW revised this review; all authors have read and approve the final manuscript.
Supported byProject of Zhejiang Traditional Chinese Medicine Technology, No. 2018ZA063; Chinese National Natural and Science Foundation, No. 81700552; and Natural Science Fund Committee of Zhejiang Province, No. LQ20C200010.
Conflict-of-interest statement: The authors declare that they have no conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Zhi Chen, Doctor, Academic Fellow, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Qingchun Road, Hangzhou 310003, Zhejiang Province, China. zjuchenzhi@zju.edu.cn
Received: April 17, 2022 Peer-review started: April 17, 2022 First decision: May 11, 2022 Revised: May 23, 2022 Accepted: August 25, 2022 Article in press: August 25, 2022 Published online: October 6, 2022 Processing time: 163 Days and 2.3 Hours
Abstract
Astragalus membranaceus Bunge, known as Huangqi, has been used to treat various diseases for a long time. Astragaloside IV (AS-IV) is one of the primary active ingredients of the aqueous Huangqi extract. Many experimental models have shown that AS-IV exerts broad beneficial effects on cardiovascular disease, nervous system diseases, lung disease, diabetes, organ injury, kidney disease, and gynaecological diseases. This review demonstrates and summarizes the structure, solubility, pharmacokinetics, toxicity, pharmacological effects, and autophagic mechanism of AS-IV. The autophagic effects are associated with multiple signalling pathways in experimental models, including the PI3KI/Akt/mTOR, PI3K III/Beclin-1/Bcl-2, PI3K/Akt, AMPK/mTOR, PI3K/Akt/mTOR, SIRT1–NF-κB, PI3K/AKT/AS160, and TGF-β/Smad signalling pathways. Based on this evidence, AS-IV could be used as a replacement therapy for treating the multiple diseases referenced above.
Core Tip: Astragaloside IV (AS-IV) is one of the main active ingredients of the aqueous extract Huangqi. Many experimental models have shown that AS-IV has broad beneficial effects on various diseases. This review demonstrates and summarizes the pharmacological effects and autophagic mechanism of AS-IV. The autophagic effects are associated with inflammation or not and multiple signalling pathways in experimental models. Based on this evidence, AS-IV will be used as replacement therapy for treating the above various diseases.
Citation: Yang Y, Hong M, Lian WW, Chen Z. Review of the pharmacological effects of astragaloside IV and its autophagic mechanism in association with inflammation. World J Clin Cases 2022; 10(28): 10004-10016
Traditional Chinese medicine (TCM) has been used to treat various diseases with great effects for a long time[1]. Radix Astragali (Huangqi) is a prevalent TCM. Compared to western medicine, TCM has significantly fewer side effects[2]. In addition to polysaccharides, flavones and amino acids, the primary components are astragalosides[3]. Astragaloside IV (AS-IV) is the primary active astragaloside, whose pharmacological effects have been reported in various diseases in vitro and in vivo. A search strategy was performed of published studies from 2001 to present using keyword searches “(astragaloside IV) and (inflamm)” in PubMed. Then we included the studies related to autophagy and excluded the studies not related to autophagy. In this review, we summarize the protective effects and autophagic mechanism of AS-IV.
PHARMACOKINETICS AND TOXICITY OF AS- IV
The Chinese Pharmacopoeia lists AS-IV as a quality test for Astragalus membranaceus[4,5]. Figure 1 shows the structural formula of AS-IV. As a cycloartane triterpene saponin (CAS number 84687-43-4), the molecular formula and molecular weight of AS-IV are C14H68O14 (Figure 1) and 784.97, respectively[4,6]. AS-IV is easily soluble in ethanol, methanol or acetone[7]. The methods of reflux, ultrafiltration, high-speed centrifugation, water extraction, ultrasonic extraction, and alcohol precipitation are combined to extract and isolate AS-IV[8].
Tissues, including kidney, lung, spleen, liver, skin, adipose tissue, heart, muscle, duodenum, brain, stomach and ovary, in rats after intravenous AS-IV, can detect AS-IV[9]. The highest concentration of AS-IV is in the liver and kidney, followed by the lung, heart and spleen[10], with limited distribution in the brain. Plasma proteins combined with AS-IV, and in urine and faeces, 50% AS-IV was recovered[9]. The linear pharmacokinetic features of AS-IV have been characterized in rats[9]. AS-IV lacks first-pass elimination and is little metabolised in the liver. The absolute bioavailability of oral administration AS-IV is 3.66% in rats and only 7.4% in beagle dogs[11], which restricts its oral administration. AS-IV causes no obvious adverse reactions or preclinical toxicity. Liver and renal function were not affected after oral administration[3,12]. In rats, no maternal toxicity appeared at doses from 0.25 to 1.0 mg/kg, but caution should be taken when using AS-IV to treat cardiovascular disease (CVD) in pregnant women at the dose of 1.0 mg/kg/d[13,14]. AS-IV exhibits maternal toxicity (intravenously guttae 1.0 mg/kg) and foetal toxicity (≥ 0.5 mg/kg) in rats, but there are no teratogenic effects in rats or rabbits[13]. The reproductive toxicity of AS-IV includes a delay in fur development, the cliff parry reflex of pups, and eye-opening under 1.0 mg/kg AS-IV for 4 wk[14]. Hence, AS-IV should be used with caution in pregnant women.
PHARMACOLOGICAL EFFECTS OF AS-IV ON VARIOUS DISEASES
AS-IV protects against various diseases, including CVD, nervous system diseases, lung disease, diabetes, organ injury, kidney disease, and gynaecological diseases. The specific diseases in each category and their related experimental models are shown in Tables 1–7.
Table 1 Protective effect of astragaloside IV on cardiovascular disease.
Disease categories
Study object/model
Effect induced by autophagy
Mechanism (targets or pathways)
Ref.
Myocardial I/R injury
H2O2 in cardiomyocytes; LAD in mice
(-) Myocardial I/R injury via (-) I/R-caused autophagosome accumulation
CVDs are pathologies related to the heart and blood vessels[15]. As the leading cause of death, CVDs have major impacts on human health and overburden the global economy[1,16]. According to current trends, the annual death toll due to CVDs will reach 22.2 million by 2030[15]. Although research on the pathophysiology and pharmacological mechanisms of CVD has progressed significantly, morbidity and mortality remain high[17]. However, many people fail to recognize the risks of CVD. High blood pressure, weight problems, and changes in glucose or cholesterol levels are all signs of CVD risk. To prevent and treat these disorders, drugs with increased therapeutic efficacy and fewer side effects are urgently needed. According to the literature, Astragalus membranaceus preparations are widely used to treat CVDs[18]. Consistently, through an autophagic mechanism, AS-IV exerts a protective effect on CVDs, including heart dysfunction, myocardial hypertrophy, and cardiomyocyte injury caused by ischaemia, hypoxic high glucose, and doxorubicin[19-24] (Table 1). AS-IV improved lipopolysaccharide (LPS)-induced cardiac dysfunction by inhibiting autophagy and regulating the expression of mitochondrial energy metabolism-related proteins[19]. By activating autophagy and decreasing inflammation, AS-IV inhibits cardiac hypertrophy caused by mechanical stress[20]. Decreased inflammation was confirmed by decreased expression of NLR family, pyrin domain containing 3 (NLRP3) and interleukin (IL)-1β[20]. Activated autophagy is demonstrated by increased microtubule-associated protein light chain 3 (LC3II) expression and decreased p62 levels. AS-IV alleviated myocardial ischaemia–reperfusion (I/R) injury by attenuating I/R-induced autophagosome accumulation, which is regulated by reactive oxygen species (ROS). AS-IV upregulated SOD2 and downregulated O2 in myocardial I/R injury in vivo and H9C2 (a subclone of the original clonal cell line which exhibits many of the properties of skeletal muscle) cardiomyocyte injury in vitro[21]. AS-IV ameliorated autophagosome numbers in H9C2 cells caused by I/R injury and decreased autophagy-related genes (Beclin-1 and LC3 II)[22]. AS-IV improves cardiomyocyte injury by inhibiting high glucose-induced oxidative stress and autophagy via the miR-34a/Bcl2/(LC3II/LC3I) and pAKT/Bcl2/(LC3II/LC3I) pathways[23]. AS-IV protected against heart damage in rats induced by doxorubicin through autophagy regulation and PI3K/Akt pathway activation[24].
Protective effect of AS-IV on the brain and nervous system
Neurological disorders include stroke, dementia, cerebral ischaemia, epilepsy, Alzheimer’s disease and Parkinson’s disease[25]. Among them, stroke is the leading cause of death worldwide[26]. Ischaemic stroke causes I/R, leading to brain injury, in which autophagy plays an important role. Huangqi has been used to treat stroke, especially in China, where it has been used for thousands of years[22]. AS-IV can cross the blood–brain barrier[26] and alleviate brain injury due to I/R through autophagy, which has been reported in several studies. AS-IV decreased cerebral I/R injury in middle cerebral artery occlusion rats. AS-IV increased autophagy in HT22 cells in vitro after oxygen and glucose deprivation/reoxygenation (OGD/R). Expression levels of the autophagy marker p62 were reduced, and the ratio of LC3II/LC3I was augmented[27]. However, Xu et al[28] found that AS-IV decreased the increased autophagy markers LC3 II, Beclin-1, and autophagy-related gene ATG12. Moreover, AS-IV (intraperitoneal injection 10 mg/kg/d) may promote functional recovery after spinal cord injury and stimulate autophagy in neuronal cells in vitro[29]. AS-IV reduced autophagic injury in PC12 cells, demonstrating that cell survival was increased and lactate dehydrogenase leakage was decreased by OGD/R. The protective mechanism is related to decreased autophagy, indicating reduced autophagosomes, reduced LC3 II/LC3 I ratio, and p62 protein upregulation. The autophagy-related mechanisms may be associated with PI3K III/Beclin-1/Bcl-2 and the PI3KI/Akt/mTOR signalling pathways[30]. AS-IV suppressed astrocyte senescence of LPS/MPP+ induced premature senescence in vitro and loss of dopamine neurons in a murine model of Parkinson’s disease. The mechanism included promotion of mitophagy, which reduced generation of mitochondrial ROS and accumulation of damaged mitochondria[31]. Table 2 lists the protective effect of AS-IV on the brain and nervous system.
Table 2 Protective effect of astragaloside IV on the brain and nervous system.
Disease categories
Study object/model
Effect induced by autophagy
Mechanism (targets or pathways)
Ref.
Ischemic stroke
MCAO in SD rats; OGD/R in HT22 cells
A neuroprotective role (-) apoptosis (+) autophagy
(+) cell viability, balanced Bcl-2 and Bax expression, (-) the rate of apoptosis, (-) p62, (+) LC3 II/LC3 I
As-IV has been reported to exert protective effects in various diseases, including non-small cell lung cancer (NSCLC), lung toxicity caused by fine particulate matter (PM2.5, < 2.5 μm), and acute respiratory distress syndrome (ARDS), which are related to autophagic mechanisms (Table 3). Lung cancer is one of the most serious diseases worldwide[32]. AS-IV not only suppresses lung cancer in vivo by enhancing immune responses[33], but also increases the chemosensitivity of NSCLC[34]. For NSCLC cells treated with cisplatin, AS-IV inhibited the increased autophagy of proteins Beclin1 and LC3 I/II[35]. Serious lung toxicity is caused by prolonged exposure to PM2.5, and no effective prevention or treatment measures currently exist[36,37]. PM2.5-induced lung toxicity in a rat model in vivo was established using PM2.5 dust suspension through intratracheal instillation. AS-IV increased autophagic flux and inflammation by activating the AMPK/mTOR pathway in rat models[36]. An ARDS model in vitro was established in MLE-12 cells induced by LPS[34], and AS-IV downregulated autophagy levels, resulting in decreased expression levels of LC3II, Beclin-1 and ATG5[34] .
Table 3 Protective effect of astragaloside IV on lung disease.
As a metabolic disorder, diabetes is marked by high levels of glucose, which can damage the kidneys, heart, eyes, gastric mucosa, and even cause coma and death[11]. AS-IV can lower blood glucose levels and can alleviate diabetic complications in diabetic mice[11]. One of the chronic diabetes complications is diabetic peripheral neuropathy (DPN), whose prevention and treatment have become a hot research topic[38]. Several studies have shown that AS-IV protects against DPN through an autophagic mechanism (Table 4). AS-IV treatment improved renal function and renal fibrosis in KK-Ay mice with spontaneous diabetes. AS-IV alleviated the overactivation of mitophagy and maintained mitochondrial function in Schwann cells, significantly downregulating expression levels of LC3 in diabetic KK-Ay mice[38]. Moreover, AS-IV prevented the progression of DPN partly through AMPKα-promoted autophagy induction[39] and exerted renoprotective effects on podocyte epithelial–mesenchymal transition through autophagy activation and modulation of the SIRT1–NF-κB pathway[40]. AS-IV also exerted neuroprotection by alleviating peripheral nerve myelin sheath injury by inhibiting autophagy and upregulating PI3K/Akt/mTOR signalling pathways[41]. A diabetic liver injury model in type 2 diabetes mellitus (T2DM) rats was induced by highfat diets/streptozotocin. ASIV treatment improved liver injury and suppressed liver autophagy in T2DM rats, which was correlated with upregulation of AMPK/mTORmediated autophagy[42] (Table 4).
Table 4 Protective effect of astragaloside IV on diabetes.
Disease categories
Study object/model
Effect induced by autophagy
Mechanism (targets or pathways)
Ref.
Diabetic peripheral neuropathy
A high-glucose medium in Schwann cells
Antioxidant activity via (-) the autophagy overactivation of Schwann cells
(-) Reactive oxygen species and (-) autophagy-related proteins (LC3, PINK and Parkin); protective effect (mitochondrial morphology and membrane potential)
Many vital roles of the liver, such as drug metabolism and detoxification, cause drug-induced liver injury. Recent studies have shown that AS-IV protects the liver from injury[11] (Table 5). LO2 cells were treated with an overdose of iron dextran, which was selected as a liver injury in the cell model. Excessive autophagy of hepatocytes was induced in this model, primarily causing hepatocyte damage. AS-IV reduced the growing number of autophagosomes, which was induced by iron dextran. LC3II/I was also significantly downregulated, and p62 was increased in the cell model. Hence, AS-IV reversed this damage by inhibiting excess autophagy[43]. Liver and kidney injuries were induced by cisplatin in rats. AS-IV plays a protective role by inducing autophagy and limiting the expression of proinflammatory mediators[44]. We found that AS-IV alleviated liver injury in acute liver failure induced by D-galactosamine/lipopolysaccharide by reducing the autophagy levels of monocytes/macrophages (data not shown).
Table 5 Protective effect of astragaloside IV on organ injury.
Disease categories
Study object/model
Effect induced by autophagy
Mechanism (targets or pathways)
Ref.
Liver injury
Iron overload (iron dextran) in LO2 cells
(-) Damage to hepatocytes, excessive autophagy, autophagosomes and apoptosis of hepatocytes by the iron overload
Kidney diseases for which AS-IV has been tested include chronic glomerulonephritis (CGN), and glomerular diseases, which are associated with autophagy treated by AS-IV (Table 6). As an immune-mediated disease, CGN is the most common glomerular disease[45]. AS-IV protects against CGN through autophagy activation via the PI3K/AKT/AS160 pathway, which is demonstrated by improved kidney function and ameliorated kidney lesions[46]. AS-IV not only alleviated fibrosis but also improved renal function and morphology in diabetic KK-Ay mice[47] (Table 6). Many glomerular diseases related to renal fibrosis are associated with mesangial cell activation. AS-IV inhibited mesangial cell activation and enhanced autophagy via the SIRT1/NF-κB p65 pathway, and these effects were eliminated by an autophagy inhibitor[47].
Table 6 Protective effect of astragaloside IV on kidney disease.
Protective effect of AS-IV on gynaecological diseases
The gynaecological diseases treated by AS-IV through an autophagic mechanism include triple-negative breast cancer, cervical cancer, and vulvar squamous cell carcinoma (VSCC) (Table 7). Triple-negative breast cancer seriously threatens women’s health worldwide. AS-IV is one of the four active ingredients of SANT (a novel Chinese herbal monomer combination) treatment. The efficacy and safety of SANT as an antitumor agent were evaluated in mouse models. SANT administration exerted significant antitumor efficacy, which enhanced autophagic flux and increased gene expression levels of ATG16L1, ATG9B and ATG4D[48]. The survival rate of advanced cervical cancer remains low. AS-IV decreased the tumour growth curves and suppressed cell invasion through autophagy induction. The autophagy regulatory proteins mRNA-decapping enzyme 1A (DCP1A) and thymosin beta-4 (TMSB4X) were increased in cervical cancer cells in response to AS-IV. Hence, by inducing autophagy, AS-IV inhibits cervical cancer invasion[49]. AS-IV also inhibited the proliferation of VSCC (SW962 cells) by increasing autophagic activity, as evidenced by increased Beclin-1 and LC3 II and decreased p62. AS-IV decreased apoptosis after autophagy inhibition by 3-methyladenine[50].
Table 7 Protective effect of astragaloside IV on gynaecological diseases.
Disease categories
Study object/model
Effect induced by autophagy
Mechanism (targets or pathways)
Ref.
Triple-negative breast cancer
The MDA-MB-231 orthotopic mammary tumour in BALB/c nude mice
(-) Cancer cells' proliferation and migration, (+) autophagy flux
(+) The ATG16L1, ATG9B, ATG4D via SANT; (-) TMEM74 and TNF gene expressions
AS-IV also has beneficial effects on gastric mucosa, flap survival, Graves’ orbitopathy (GO), and so on. AS-IV protected the gastric mucosa in a rat model and decreased expression levels of the autophagic proteins Beclin1, p62, ATG5 and ATG12[51]. AS-IV may have beneficial functions for flap survival. AS-IV increased the flap survival area and reduced tissue oedema. AS-IV promoted survival of skin flaps decreased tissue oedema by activating autophagy in a rat model[52]. AS-IV significantly decreased IL-1β secretion in influenza A (H1N1) infection by activating autophagy[53]. AS-IV decreased inflammatory responses and reduced excessive autophagy induced by heat in vitro and in vivo[54]. AS-IV or rapamycin played an antiapoptotic role by increasing autophagic activity in IL-1β-treated chondrocytes[55]. GO is a disease affecting the cornea of the eye. AS-IV protects against GO orbital inflammation by suppressing autophagy induced by IL-1β[56].
THE AUTOPHAGY PROMOTING OR INHIBITORY EFFECTS OF AS-IV
AS-IV promotes or inhibits autophagy to exert beneficial effects on various diseases. The related signalling pathways of the autophagic mechanism are shown in Table 8. AS-IV promotes or inhibits autophagy to alleviate inflammation and disease severity (Figure 2). AS-IV also promotes or inhibits autophagy to alleviate disease severity not associated with inflammation (Figure 2).
The autophagy-promoting effects of AS-IV are associated with inflammation
AS-IV has beneficial effects on various diseases by promoting autophagy to alleviate inflammation. These diseases include lung injury induced by PM2.5, liver injury in type 2 diabetic rats, acute spinal cord injury, myocardial hypertrophy, H1N1 infection, and flap survival.
AS-IV protected against PM2.5-induced lung toxicity in rats and in vitro through increasing autophagic flux and inhibiting severe inflammation[36,37]. The inflammatory mediators granulocyte-macrophage colony-stimulating factor, intercellular adhesion molecule 1, tumour necrosis factor (TNF) α, IL 6, IL-18 and C-reactive protein were inhibited by AS-IV[36,37]. The associated mechanism includes the AMPK/mTOR or PI3K/Akt/mTOR pathway[36,37]. AS-IV induced autophagic flux depending on AMPK activation and inhibiting phosphorylation of mTOR[36]. AS-IV primarily restored autophagic flux through autophagosome degradation and increased autophagosome-lysosome fusion[37]. AS-IV significantly inhibited the protein expression of phosphorylated phosphatidylinositol 3-kinase (p-PI3K), p-Akt and phosphorylated mechanistic target of rapamycin (p-mTOR)[37].
ASIV promoted autophagy through the AMPK/mTOR signalling pathway to further inhibit expression of TNFα and IL6 and protect against liver injury in T2DM rats[42]. ASIV reversed the suppression of the AMPK/mTOR pathway, elevated the pAMPK/AMPK ratio and reduced the pmTOR/mTOR ratio[42]. AS-IV induced autophagy to protect against liver and kidney injury in rats induced by cisplatin, inhibiting the expression of inflammatory mediators, such as the NLRP3 inflammasome[44]. AS-IV may promote functional recovery in vivo after spinal cord injury through a mechanism related to autophagy promotion and inflammatory inhibition, such as the downregulated expression of inducible NO synthase, cyclo-oxygenase-2 and TNF-α. AS-IV may promote autophagy in neuronal cells to inhibit apoptosis and polarize towards an M2 phenotype in microglial cells to attenuate neuroinflammation[29]. AS-IV activated autophagy and reduced the inflammatory mediators NLRP3 and IL-1β in cardiomyocytes, preventing hypertrophy and improving cardiac function induced by mechanical stress[20]. AS-IV activated autophagy triggered by H1N1 infection to reduce secretion of the inflammatory mediator IL-1β[53]. AS-IV promoted skin flap survival via autophagic activation in the rat McFarlane flap model[52]. The related mechanism also involved inflammatory inhibition, which was evidenced by decreased expression levels of TNF-α, IL-1β and IL6 and inhibited leukocyte infiltration[52].
The autophagy-promoting effects of AS-IV are not associated with inflammation
Diseases that benefit from the autophagic mechanism of AS-IV are not related to inflammation and include cancer, diabetes, nervous system diseases, and CVDs.
AS-IV exerted anticancer effects on lung cancer, lung adenocarcinoma cells, VSCC, and the gastric mucosa. AS-IV promoted autophagy mediated by the p53/AMPK/mTOR signalling pathway and was favourable in lung cancer[32]. AS-IV enhanced autophagy levels associated with the AKT and mTOR pathways, which was inhibited by bevacizumab in lung adenocarcinoma cells[57]. AS-IV induced autophagy and inhibited cell proliferation in VSCC, which was associated with the TGF-β/Smad pathway[50]. AS-IV promoted the expression level of the autophagy proteins Beclin1, p62, ATG5, and ATG12 to have a beneficial effect on gastric mucosa in vivo[51].
AS-IV exerted beneficial effects on diabetic complications, such as DPN and liver injury. AS-IV activated autophagy to improve renal fibrosis and function in diabetic KK-Ay mice, while an autophagy inhibitor abrogated the effect of AS-IV[40,47]. AS-IV induced autophagy promoted by AMPKα to inhibit DPN progression[39]. AS-IV enhanced autophagy to alleviate myelin sheath injury in DPN induced by Schwann cell apoptosis. Enhanced autophagy was associated with inhibition of the PI3K/Akt/mTOR signalling pathway[41]. ASIV promoted autophagy mediated by the AMPK/mTOR pathway to alleviate liver injury and insulin resistance in diabetic rats[42] .
AS-IV exerts a protective role against senescent astrocytes, ischaemic stroke, CVD and arthritis. AS-IV induced mitophagy to reduce astrocyte senescence, which is involved in PD[31]. I/R caused by ischaemic stroke leads to brain injury, and autophagy reduction plays a role in its pathology, which can be reversed by AS-IV[27]. AS-IV-induced mitochondrial autophagy has favourable effects on mitochondrial dysfunction in rat vascular smooth muscle cells induced by Ang II[58]. Autophagy was promoted by AS-IV or rapamycin to reduce chondrocyte apoptosis caused by IL-1β[55] .
The autophagy inhibition effects of AS-IV are associated with inflammation
AS-IV has beneficial effects on various diseases through autophagy inhibition to alleviate inflammation. These diseases include acute respiratory distress syndrome, kidney disease, GO, and thermal injury. For the pulmonary endothelial ARDS cell model stimulated by LPS, AS-IV inhibited inflammation and apoptosis to limit autophagy initiation, which was evidenced by the downregulated expression of autophagy proteins[34]. AS-IV-activated autophagy is associated with inhibition of the PI3K/ AKT/AS160 pathway to reduce kidney injury and inhibit inflammation in CGN rats[45]. AS-IV suppresses autophagy to reduce the expression of inflammatory mediators such as IL-6, IL-8, TNF-α, and monocyte chemoattractant protein-1, thus protecting against GO[56]. AS-IV alleviated excessive autophagy and inflammatory responses induced by heat injury in vitro and in vivo. Autophagy induced by heat stress can activate and cross talk with the PERK/eIF2α pathway[54].
The autophagy inhibition effects of AS-IV are not associated with inflammation
AS-IV exerts beneficial effects on various diseases through autophagy inhibition, which is not associated with inflammation. These diseases include heart diseases, CVD, nerve injury, liver injury, lung injury, and cancer.
AS-IV can reduce ROS-mediated autophagosome accumulation and myocardial injury caused by I/R[21]. AS-IV inhibits the cardiotoxicity of rats via autophagy inhibition and PI3K/Akt pathway activation[21]. AS-IV decreased apoptosis and autophagosome number, which were increased in hypoxia/ reoxygenation-injured H9C2 cells[21]. AS-IV inhibited autophagy and improved heart dysfunction induced by LPS[19]. AS-IV inhibited HG-induced autophagy and improved cardiac dysfunction[23]. AS-IV inhibited autophagy and decreased mineralization in in vitro and in vivo models of atherosclerosis[59]. AS-IV reversed the upregulation of autophagic proteins, such as Beclin-1, LC3II and ATG12, caused by the intestinal microbiota[28]. AS-IV blocked excessive autophagy injury in PC12 cells in response to OGD/R[30]. AS-IV inhibited mitophagy and excessive autophagy in Schwann cells induced by high glucose[38]. AS-IV reduced the number of autophagosomes and excessive autophagy, alleviating the damage to L02 hepatocytes induced by iron overload[43]. AS-IV degraded autophagosomes to alleviate lung injury caused by PM2.5 in vivo and in vitro[37]. AS-IV inhibited autophagy to counteract chemoresistance in NSCLC cells treated with cisplatin[35]. AS-IV induces autophagy to inhibit the invasion of cervical cancer[49].
CONCLUSION
AS-IV, the primary active astragaloside from Radix Astragali, has been reported to have pharmacological effects on various diseases. The pharmacokinetics characterization revealed that AS-IV was detected in 12 tissues, including the liver and kidney. AS-IV not only promotes but also inhibits autophagic activity through a variety of signalling pathways to improve various diseases. These pathways include the PI3K I/Akt/mTOR, PI3K III/Beclin-1/Bcl-2, PI3K/Akt, AMPK/mTOR, PI3K/Akt/mTOR, SIRT1–NF-κB, PI3K/AKT/AS160, and TGF-β/Smad signalling pathways. The suggested pathway in this literature review is that the autophagic proteins Atg7/Atg12 are mediated by DCP1A and TMSB4X. When the level of Atg7/Atg12 is reduced, the level of DCP1A and TMSB4X is also decreased. The autophagy-related proteins include Beclin-1, LC3II, p62, ATG16L1, ATG9B and ATG4D. AS-IV is distributed widely in various tissues and the autophagic mechanism of AS-IV is a basic biological mechanism. Hence, AS-IV is an effective therapeutic drug for various diseases. According to existing research, AS-IV possesses the potential for broad application in many diseases, and the autophagy mechanism deserves further investigation.
Footnotes
Provenance and peer review: Unsolicited article; Externally peer reviewed.
Buttar HS, Li T, Ravi N. Prevention of cardiovascular diseases: Role of exercise, dietary interventions, obesity and smoking cessation.Exp Clin Cardiol. 2005;10:229-249.
[PubMed] [DOI][Cited in This Article: ]
Chinese Pharmacopoeia Commission Pharmacopoeia of the People’s Republic of China.
Beijing: China medical science and technology press, 2015: 302.
[PubMed] [DOI][Cited in This Article: ]
Sun GX, Zhao YY, Miao PP, Yang XY, Miao Q, Li J, Xue BJ, Su J, Zhang YJ. [Stability study in biological samples and metabolites analysis of astragaloside IV in rat intestinal bacteria in vitro].Zhongguo Zhong Yao Za Zhi. 2014;39:4258-4264.
[PubMed] [DOI][Cited in This Article: ]
Wang Q, Yang X, Song Y, Sun X, Li W, Zhang L, Hu X, Wang H, Zhao N, Zhuang R, Xie X, Tang F. Astragaloside IV-targeting miRNA-1 attenuates lipopolysaccharide-induced cardiac dysfunction in rats through inhibition of apoptosis and autophagy.Life Sci. 2021;275:119414.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 7][Cited by in F6Publishing: 20][Article Influence: 6.7][Reference Citation Analysis (0)]
Zhang T, Wang H, Lu M, Zhao K, Yin J, Liu Y, Sun Y. Astragaloside IV prevents myocardial hypertrophy induced by mechanical stress by activating autophagy and reducing inflammation.Am J Transl Res. 2020;12:5332-5342.
[PubMed] [DOI][Cited in This Article: ]
Huang KY, Yu YW, Liu S, Zhou YY, Wang JS, Peng YP, Ji KT, Xue YJ. A Single, Acute Astragaloside IV Therapy Protects Cardiomyocyte Through Attenuating Superoxide Anion-Mediated Accumulation of Autophagosomes in Myocardial Ischemia-Reperfusion Injury.Front Pharmacol. 2021;12:642925.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 2][Cited by in F6Publishing: 3][Article Influence: 1.0][Reference Citation Analysis (0)]
Lin J, Pan X, Huang C, Gu M, Chen X, Zheng X, Shao Z, Hu S, Wang B, Lin H, Wu Y, Tian N, Gao W, Zhou Y, Zhang X, Wang X. Dual regulation of microglia and neurons by Astragaloside IV-mediated mTORC1 suppression promotes functional recovery after acute spinal cord injury.J Cell Mol Med. 2020;24:671-685.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 18][Cited by in F6Publishing: 33][Article Influence: 6.6][Reference Citation Analysis (0)]
Guo H, Wang Y, Zhang X, Zang Y, Zhang Y, Wang L, Wang H, Cao A, Peng W. Astragaloside IV protects against podocyte injury via SERCA2-dependent ER stress reduction and AMPKα-regulated autophagy induction in streptozotocin-induced diabetic nephropathy.Sci Rep. 2017;7:6852.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 44][Cited by in F6Publishing: 80][Article Influence: 11.4][Reference Citation Analysis (0)]
Li QW, Zhang GL, Hao CX, Ma YF, Sun X, Zhang Y, Cao KX, Li BX, Yang GW, Wang XM. SANT, a novel Chinese herbal monomer combination, decreasing tumor growth and angiogenesis via modulating autophagy in heparanase overexpressed triple-negative breast cancer.J Ethnopharmacol. 2021;266:113430.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 6][Cited by in F6Publishing: 9][Article Influence: 3.0][Reference Citation Analysis (0)]
Lin R, Chen H, Callow D, Li S, Wang L, Chen L, Ding J, Gao W, Xu H, Kong J, Zhou K. Multifaceted effects of astragaloside IV on promotion of random pattern skin flap survival in rats.Am J Transl Res. 2017;9:4161-4172.
[PubMed] [DOI][Cited in This Article: ]
